Medtronic (NYSE: MDT) announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

Medtronic CRT-D Devices Demonstrate Survival Benefits for Mildly Symptomatic Heart Failure Patients in Two Pivotal Clinical Trials MINNEAPOLIS – Medtronic, Inc. today announced that the U.S. Food and ...

Results from the Cardiac Resynchronization—Heart Failure (CARE-HF) study support the use of implantable cardiac-resynchronization devices in patients with heart failure due to left-ventricular ...

Wearable electronic devices such as smart watches, worn by consumers to monitor their health, could interfere with the correct working of cardiac implantable electronic devices (CIEDs), posing serious ...

Multiple societies covering cardiovascular medicine, electrophysiology, heart failure, and imaging have released updated appropriate use criteria (AUC) for various cardiac implantable electronic ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

A widely anticipated heart disease study released Tuesday could boost the use of an advanced type of heart defibrillator made by companies with strong roots in Minnesota. The 1,820-patient study -- ...

The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...